{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:52:33Z","timestamp":1792799553019,"version":"4.5.0"},"reference-count":60,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503128"],"award-info":[{"award-number":["82503128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Tenth People\u2019s Hospital","award":["2023YJXYSB004"],"award-info":[{"award-number":["2023YJXYSB004"]}],"id":[{"id":"https:\/\/ror.org\/03vjkf643","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010167","name":"Shanghai Shen Kang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2024CRI032"],"award-info":[{"award-number":["SHDC2024CRI032"]}],"id":[{"id":"10.13039\/501100010167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["202140150"],"award-info":[{"award-number":["202140150"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People\u2019s Republic of China","doi-asserted-by":"publisher","award":["WKZX2024CX104102"],"award-info":[{"award-number":["WKZX2024CX104102"]}],"id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2022-03-8"],"award-info":[{"award-number":["320.6750.2022-03-8"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017633","name":"Shanghai Anti-Cancer Association","doi-asserted-by":"publisher","award":["CETSDHRCORP252-3-044"],"award-info":[{"award-number":["CETSDHRCORP252-3-044"]}],"id":[{"id":"10.13039\/100017633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8250113543"],"award-info":[{"award-number":["8250113543"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Outstanding Resident Clinical Postdoctoral Program of Zhongshan Hospital"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Metastatic hormone-sensitive prostate cancer (mHSPC) often progresses to castration-resistant prostate cancer despite current therapies, necessitating the use of reliable biomarkers. This study aimed to develop a novel model for predicting progression-free survival (PFS) using ctDNA sequencing. We analyzed 127 patients with mHSPC and compared ctDNA mutations with those in matched primary tumor tissues. A four-gene signature (TRPC: TP53, RB1, PTEN, and CDK12) was identified, forming the basis of the blood-based TRPC (b.TRPC) model. The b.TRPC model demonstrated high specificity and sensitivity in predicting PFS, outperforming ctDNA markers. Internal and external validation confirmed that b.TRPC is an independent prognostic factor with superior predictive performance for 0.5-, 1-, and 2-year PFS. The model also showed significant clinical relevance, with b.TRPC-positive patients exhibiting shorter survival times under androgen deprivation therapy and doublet therapy, although this disparity diminished with triplet therapy. These findings highlight the potential of ctDNA-based gene mutation analysis to guide personalized treatment strategies for mHSPC, offering a noninvasive alternative to tissue-based analyses and improving prognostic accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study identified a novel noninvasive blood-based biomarker model (b.TRPC) using ctDNA to predict PFS in mHSPC. Analyzing TP53, RB1, PTEN, and CDK12 alterations, it outperformed traditional ctDNA% markers. Findings highlight ctDNA-based biomarkers\u2019 potential to guide personalized treatment, bridging real-world and trial data to aid mHSPC management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0384","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:27:35Z","timestamp":1762878455000},"page":"2092-2101","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in\n                    <i>De Novo<\/i>\n                    Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5508-2785","authenticated-orcid":false,"given":"Ruiliang","family":"Wang","sequence":"first","affiliation":[{"name":"1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0689-7783","authenticated-orcid":false,"given":"Jing","family":"Xu","sequence":"additional","affiliation":[{"name":"2Department of Urology, Shanghai Tenth People\u2019s Hospital, Tongji University School of Medicine, Shanghai, China."},{"name":"3Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5334-7996","authenticated-orcid":false,"given":"Chenyi","family":"Zhu","sequence":"additional","affiliation":[{"name":"2Department of Urology, Shanghai Tenth People\u2019s Hospital, Tongji University School of Medicine, Shanghai, China."},{"name":"3Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8208-4348","authenticated-orcid":false,"given":"Wujianhong","family":"Liu","sequence":"additional","affiliation":[{"name":"3Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China."},{"name":"4Department of Pathology, Shanghai Tenth People\u2019s Hospital, Tongji University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7684-772X","authenticated-orcid":false,"given":"Chengqi","family":"Jin","sequence":"additional","affiliation":[{"name":"2Department of Urology, Shanghai Tenth People\u2019s Hospital, Tongji University School of Medicine, Shanghai, China."},{"name":"3Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8549-2480","authenticated-orcid":false,"given":"Wentao","family":"Luo","sequence":"additional","affiliation":[{"name":"2Department of Urology, Shanghai Tenth People\u2019s Hospital, Tongji University School of Medicine, Shanghai, China."},{"name":"3Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3003-2779","authenticated-orcid":false,"given":"Tingting","family":"Zhao","sequence":"additional","affiliation":[{"name":"5School of Life Sciences and Technology, Tongji University, Shanghai, China."},{"name":"6Research Institute, GloriousMed Clinical Laboratory, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9145-2384","authenticated-orcid":false,"given":"Changcheng","family":"Guo","sequence":"additional","affiliation":[{"name":"2Department of Urology, Shanghai Tenth People\u2019s Hospital, Tongji University School of Medicine, Shanghai, China."},{"name":"3Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2139-1368","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-8035","authenticated-orcid":false,"given":"Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"2Department of Urology, Shanghai Tenth People\u2019s Hospital, Tongji University School of Medicine, Shanghai, China."},{"name":"3Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2025113022534938600_bib1","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2025113022534938600_bib2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.eururo.2015.02.042","article-title":"Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer","volume":"68","author":"Buzzoni","year":"2015","journal-title":"Eur Urol"},{"key":"2025113022534938600_bib3","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1002\/cncr.31384","article-title":"Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts","volume":"124","author":"Helgstrand","year":"2018","journal-title":"Cancer"},{"key":"2025113022534938600_bib4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"2025113022534938600_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/jamaoncol.2023.0324","article-title":"Triplet therapy in metastatic hormone-sensitive prostate cancer-calling out the \u201cdouble standard\u201d","volume":"9","author":"McHugh","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025113022534938600_bib6","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025113022534938600_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis","volume":"9","author":"Mandel","year":"2023","journal-title":"Eur Urol Focus"},{"key":"2025113022534938600_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/CM9.0000000000003311","article-title":"De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: network-analysis and systematic review","volume":"138","author":"Guo","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"2025113022534938600_bib9","first-page":"232","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"22","author":"Huggins","year":"1972","journal-title":"CA Cancer J Clin"},{"key":"2025113022534938600_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"2025113022534938600_bib11","doi-asserted-by":"crossref","first-page":"101937","DOI":"10.1016\/j.xcrm.2025.101937","article-title":"Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence","volume":"6","author":"Arce-Gallego","year":"2025","journal-title":"Cell Rep Med"},{"key":"2025113022534938600_bib12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"2025113022534938600_bib13","doi-asserted-by":"crossref","first-page":"e2437871","DOI":"10.1001\/jamanetworkopen.2024.37871","article-title":"Circulating tumor cell count and overall survival in patients with metastatic hormone-sensitive prostate cancer","volume":"7","author":"Goldkorn","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025113022534938600_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.eururo.2023.03.036","article-title":"Bone biomarkers and subsequent survival in men with hormone-sensitive prostate cancer: results from the SWOG S1216 phase 3 trial of androgen deprivation therapy with or without orteronel","volume":"85","author":"Lara","year":"2024","journal-title":"Eur Urol"},{"key":"2025113022534938600_bib15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/pros.24754","article-title":"Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients","volume":"84","author":"Wenzel","year":"2024","journal-title":"Prostate"},{"key":"2025113022534938600_bib16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.euo.2024.02.005","article-title":"Olaparib combined with abiraterone versus olaparib monotherapy for patients with metastatic castration-resistant prostate cancer progressing after abiraterone and harboring DNA damage repair deficiency: a multicenter real-world study","volume":"7","author":"Xie","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2025113022534938600_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"2025113022534938600_bib18","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/ncomms7605","article-title":"Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer","volume":"6","author":"Hong","year":"2015","journal-title":"Nat Commun"},{"key":"2025113022534938600_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s11658-023-00450-z","article-title":"Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment","volume":"28","author":"Yu","year":"2023","journal-title":"Cell Mol Biol Lett"},{"key":"2025113022534938600_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025113022534938600_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/1078-0432.CCR-21-3577","article-title":"Olaparib efficacy in patients with metastatic castration-resistant prostate cancer and BRCA1, BRCA2, or ATM alterations identified by testing circulating tumor DNA","volume":"29","author":"Matsubara","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025113022534938600_bib22","doi-asserted-by":"crossref","first-page":"101701","DOI":"10.1016\/j.tranon.2023.101701","article-title":"Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer","volume":"34","author":"Du","year":"2023","journal-title":"Transl Oncol"},{"issue":"Suppl 6","key":"2025113022534938600_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.2021.39.6_suppl.26","article-title":"Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025113022534938600_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"2025113022534938600_bib25","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/2767-9764.CRC-23-0175","article-title":"Concordance and clinical significance of genomic alterations in progressive tumor tissue and matched circulating tumor DNA in aggressive-variant prostate cancer","volume":"3","author":"Wang","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2025113022534938600_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s43018-023-00692-y","article-title":"Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping","volume":"5","author":"Warner","year":"2024","journal-title":"Nat Cancer"},{"key":"2025113022534938600_bib27","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025113022534938600_bib28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.euo.2021.10.005","article-title":"Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: a systematic review","volume":"4","author":"Van der Eecken","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2025113022534938600_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13046-025-03356-0","article-title":"Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer","volume":"44","author":"N\u00f8rgaard","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"2025113022534938600_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","article-title":"Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer","volume":"608","author":"Herberts","year":"2022","journal-title":"Nature"},{"key":"2025113022534938600_bib31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eururo.2018.12.042","article-title":"Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer","volume":"75","author":"Vandekerkhove","year":"2019","journal-title":"Eur Urol"},{"key":"2025113022534938600_bib32","doi-asserted-by":"crossref","first-page":"108931","DOI":"10.1016\/j.isci.2024.108931","article-title":"Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer","volume":"27","author":"Yang","year":"2024","journal-title":"iScience"},{"key":"2025113022534938600_bib33","doi-asserted-by":"crossref","first-page":"905","DOI":"10.6004\/jnccn.2020.7663","article-title":"Use of circulating tumor DNA for the clinical management of metastatic castration-resistant prostate cancer: a multicenter, real-world study","volume":"19","author":"Dong","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2025113022534938600_bib34","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"2025113022534938600_bib35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2025113022534938600_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"2025113022534938600_bib37","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.eururo.2017.07.024","article-title":"AR-V7 in peripheral whole blood of patients with castration-resistant prostate cancer: association with treatment-specific outcome under abiraterone and enzalutamide","volume":"72","author":"Seitz","year":"2017","journal-title":"Eur Urol"},{"key":"2025113022534938600_bib38","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"key":"2025113022534938600_bib39","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer","volume":"28","author":"Jee","year":"2022","journal-title":"Nat Med"},{"key":"2025113022534938600_bib40","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.3390\/cancers14092219","article-title":"Baseline plasma tumor DNA (ctDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide","volume":"14","author":"Conteduca","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025113022534938600_bib41","doi-asserted-by":"crossref","first-page":"102728","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"key":"2025113022534938600_bib42","doi-asserted-by":"crossref","first-page":"k3519","DOI":"10.1136\/bmj.k3519","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"Ilic","year":"2018","journal-title":"BMJ"},{"key":"2025113022534938600_bib43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.annonc.2023.06.001","article-title":"Fragmentomic analysis of circulating tumor DNA-targeted cancer panels","volume":"34","author":"Helzer","year":"2023","journal-title":"Ann Oncol"},{"key":"2025113022534938600_bib44","doi-asserted-by":"crossref","first-page":"djx118","DOI":"10.1093\/jnci\/djx118","article-title":"Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer","volume":"109","author":"Wyatt","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2025113022534938600_bib45","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/cncr.31959","article-title":"Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer","volume":"125","author":"Sonpavde","year":"2019","journal-title":"Cancer"},{"key":"2025113022534938600_bib46","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ijc.31397","article-title":"Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide","volume":"143","author":"Belic","year":"2018","journal-title":"Int J Cancer"},{"key":"2025113022534938600_bib47","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"2025113022534938600_bib48","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"2025113022534938600_bib49","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2025113022534938600_bib50","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"2025113022534938600_bib51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","article-title":"Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer","volume":"76","author":"Hamid","year":"2019","journal-title":"Eur Urol"},{"key":"2025113022534938600_bib52","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.euo.2023.12.012","article-title":"Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients","volume":"7","author":"Jim\u00e9nez","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2025113022534938600_bib53","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41391-021-00430-4","article-title":"Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer","volume":"25","author":"Velez","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025113022534938600_bib54","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1158\/1078-0432.CCR-20-0168","article-title":"Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer","volume":"26","author":"Stopsack","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025113022534938600_bib55","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/PO.19.00399","article-title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD-1 inhibitors","volume":"4","author":"Antonarakis","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2025113022534938600_bib56","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.eururo.2020.03.024","article-title":"Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics","volume":"78","author":"Nguyen","year":"2020","journal-title":"Eur Urol"},{"key":"2025113022534938600_bib57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2019.09.036","article-title":"Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer","volume":"77","author":"Reimers","year":"2020","journal-title":"Eur Urol"},{"key":"2025113022534938600_bib58","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"2025113022534938600_bib59","first-page":"81","article-title":"Systemic triple therapy in metastatic hormone sensitive prostate cancer (mHSPC)","volume":"61","author":"Omr\u010den","year":"2022","journal-title":"Acta Clin Croat"},{"key":"2025113022534938600_bib60","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0384\/3670070\/crc-25-0384.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/12\/2092\/3708211\/crc-25-0384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/12\/2092\/3708211\/crc-25-0384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T03:54:03Z","timestamp":1764561243000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/12\/2092\/770308\/Blood-Based-Genomic-Alteration-Signature-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0384","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30748429","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748426","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748447","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748414","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748417","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748438","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748411","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748444","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748432","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748435","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748423","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748456","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748450","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748453","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748420","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30748441","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8176084","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}